← All Quantumzyme CORP filings

Quantumzyme CORP 8-K filings

Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.

QTZM
Quantumzyme CORP
8-K: Quantum Genesis AI Corp. Formalizes IP Assignment
Quantum Genesis AI Corp. has formalized the assignment of a key patent application related to ibuprofen synthesis from its CEO, Naveen Kulkarni, effective retroactively to the application's filing date.
QTZM
Quantumzyme CORP
8-K: Quantumzyme Rebrands to Quantum Genesis AI, Changes Symbol
Quantumzyme Corp. has officially changed its name to Quantum Genesis AI Corp. and will trade under the new symbol QGAI effective February 17, 2026.
QTZM
Quantumzyme CORP
8-K: Quantumzyme Rebrands to Quantum Genesis AI Corp.
Quantumzyme Corp. announced its Board and majority shareholders approved a name change to Quantum Genesis AI Corp., pending regulatory filings.